---
title: "Tension-Type Headache"
description: "Clinical decision support for tension-type headache diagnosis and management across care settings"
version: "1.1"
setting: "ED, HOSP, OPD"
status: approved
tags:
  - headache
  - tension-type-headache
  - outpatient
  - primary-headache
---

# Tension-Type Headache

**DIAGNOSIS:** Tension-Type Headache
**ICD-10:** G44.209 (Tension-type headache, unspecified, not intractable); G44.219 (Episodic tension-type headache, not intractable); G44.221 (Chronic tension-type headache, not intractable)
**SYNONYMS:** TTH; Tension headache; Muscle contraction headache; Stress headache; Chronic tension-type headache; Episodic tension-type headache
**SCOPE:** Episodic and chronic tension-type headache diagnosis, acute treatment, and preventive therapy. Excludes secondary headaches, medication overuse headache (separate protocol), and trigeminal autonomic cephalalgias.

**VERSION:** 1.1
**CREATED:** January 27, 2026
**REVISED:** January 30, 2026

**STATUS:** Approved

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| CBC (85025) | STAT | ROUTINE | ROUTINE | - | Rule out anemia or infection as headache trigger | Normal |
| BMP (80048) | STAT | ROUTINE | ROUTINE | - | Electrolyte abnormalities can trigger headaches | Normal |
| TSH (84443) | - | ROUTINE | ROUTINE | - | Hypothyroidism associated with chronic headache | Normal (0.4-4.0 mIU/L) |

### 1B. Extended Workup (Second-line)

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| ESR, CRP (85652/86140) | URGENT | ROUTINE | ROUTINE | - | Rule out giant cell arteritis if age >50 with new headache | Normal |
| Vitamin D (82306) | - | ROUTINE | ROUTINE | - | Deficiency associated with chronic pain and headache | >30 ng/mL |
| Ferritin (82728) | - | ROUTINE | ROUTINE | - | Iron deficiency associated with headache | >50 ng/mL |
| Magnesium, RBC (83735) | - | ROUTINE | ROUTINE | - | Low magnesium linked to headache disorders | >4.2 mg/dL |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| ANA (86038) | - | EXT | EXT | - | Rule out autoimmune disorder in atypical presentations | Negative |
| Sleep study (95811) | - | - | EXT | - | Evaluate for sleep apnea contributing to chronic headache | AHI <5 |
| Lyme serology (86618) | - | EXT | EXT | - | Consider in endemic areas with refractory symptoms | Negative |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| MRI Brain without contrast (70551) | URGENT | ROUTINE | ROUTINE | - | Only if red flags present (see SNNOOP10 below) | Normal | MRI-incompatible devices |
| CT Head non-contrast (70450) | STAT | STAT | - | - | Acute severe headache or new neurological deficits | No hemorrhage, mass, or hydrocephalus | Pregnancy (relative) |

### 2B. Extended

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| MRI Brain with contrast (70553) | URGENT | ROUTINE | ROUTINE | - | Atypical features, focal deficits, suspected secondary cause | No enhancement or mass lesion | Gadolinium allergy, severe renal impairment |
| MRA Head/Neck (70544/70547) | URGENT | ROUTINE | EXT | - | Suspected vascular etiology or cervical artery dissection | Patent vessels; no dissection | MRI contraindications |
| C-spine X-ray or MRI (72050/72141) | - | ROUTINE | ROUTINE | - | Cervicogenic component suspected | Normal alignment; no disc disease | None |

### 2C. Rare/Specialized

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| MRV Brain (70546) | URGENT | ROUTINE | EXT | - | Suspected cerebral venous thrombosis | Patent venous sinuses | MRI contraindications |
| LP with opening pressure (62270) | - | ROUTINE | EXT | - | Suspected idiopathic intracranial hypertension | Normal (10-20 cm H2O) | Coagulopathy; mass lesion |

---

**IMAGING RED FLAGS (SNNOOP10):** Imaging indicated if any of the following:
- **S**ystemic symptoms (fever, weight loss) or systemic disease (HIV, cancer)
- **N**eurological symptoms or abnormal signs
- **N**ew onset or sudden onset (thunderclap)
- **O**nset after age 50
- **O**ther associated conditions (pregnancy, postpartum, immunosuppression)
- **P**attern change from previous headaches
- **P**ositional (worse lying down or standing)
- **P**recipitated by Valsalva (cough, sneeze, exertion)
- **P**apilledema
- **P**rogressive headache or atypical features
- **P**ainful eye with autonomic features

---

## 3. TREATMENT

### ICHD-3 Diagnostic Criteria for Tension-Type Headache

**Episodic TTH (<15 days/month):**
A. At least 10 episodes fulfilling criteria B-D
B. Lasting 30 minutes to 7 days
C. At least 2 of: bilateral location; pressing/tightening (non-pulsating) quality; mild-moderate intensity; not aggravated by routine physical activity
D. Both: no nausea or vomiting; no more than one of photophobia or phonophobia
E. Not better accounted for by another ICHD-3 diagnosis

**Chronic TTH (≥15 days/month for >3 months):**
Same as above but occurring ≥15 days/month on average for >3 months

---

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Ketorolac | IV/IM | Severe acute TTH in ED; NSAID-responsive headache | 30 mg :: IV :: x1 :: 30 mg IV x1 (15 mg if >65y, renal impairment, or <50 kg); do not exceed 5 days total NSAIDs | Renal impairment; GI bleed history; aspirin allergy; third trimester pregnancy | Renal function if repeated dosing | STAT | URGENT | - | - |
| Metoclopramide | IV | Acute headache with nausea; has anti-headache properties | 10 mg :: IV :: x1 :: 10 mg IV over 15 min; pretreat with diphenhydramine 25 mg to prevent akathisia | Parkinson's disease; tardive dyskinesia history; bowel obstruction | Akathisia, dystonic reaction | URGENT | URGENT | - | - |
| Diphenhydramine | IV | Adjunct to prevent akathisia from dopamine antagonists | 25 mg :: IV :: x1 :: 25 mg IV prior to metoclopramide | Narrow-angle glaucoma; urinary retention | Sedation | URGENT | URGENT | - | - |

### 3B. Symptomatic Treatments

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Ibuprofen | PO | First-line acute treatment for episodic TTH | 400 mg :: PO :: PRN :: 400-800 mg PO at onset; may repeat q6-8h; max 2400 mg/day; limit to <10 days/month | Renal impairment; GI bleed history; aspirin allergy; third trimester | GI symptoms; renal function if prolonged use | URGENT | ROUTINE | ROUTINE | - |
| Naproxen | PO | First-line acute treatment; longer duration than ibuprofen | 500 mg :: PO :: PRN :: 500-550 mg PO at onset; may repeat 250 mg in 12 hr; max 1250 mg/day; limit to <10 days/month | Renal impairment; GI bleed history; aspirin allergy; third trimester | GI symptoms; renal function if prolonged use | URGENT | ROUTINE | ROUTINE | - |
| Acetaminophen | PO | First-line if NSAID contraindicated; mild-moderate TTH | 1000 mg :: PO :: PRN :: 1000 mg PO at onset; may repeat q6h; max 3000 mg/day (2000 mg if liver disease); limit to <10 days/month | Severe hepatic impairment; avoid if >3 alcoholic drinks/day | LFTs if chronic use; total daily dose from all sources | URGENT | ROUTINE | ROUTINE | - |
| Aspirin | PO | First-line acute treatment; anti-inflammatory | 650 mg :: PO :: PRN :: 650-1000 mg PO at onset; max 4000 mg/day; limit to <10 days/month | Bleeding disorders; GI ulcer; aspirin allergy; children/teens (Reye syndrome); third trimester | GI symptoms; bleeding | URGENT | ROUTINE | ROUTINE | - |
| Caffeine/Analgesic combination | PO | Enhanced efficacy with caffeine adjunct | 2 tablets :: PO :: PRN :: Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: 2 tablets at onset; max 2 doses/24hr | Aspirin or acetaminophen contraindications | Limit use to prevent caffeine dependence and MOH | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Trigger point injection | IM | Pericranial muscle tenderness; refractory to oral therapy | 1-2 mL :: IM :: q2-4wk :: Inject 1-2 mL 1% lidocaine into tender points in trapezius, temporalis, or cervical paraspinals; may repeat q2-4wk | Local anesthetic allergy; infection at site | Local bruising; vasovagal response | - | EXT | ROUTINE | - |
| Greater occipital nerve block | SC | Occipital-predominant pain; refractory cases | 2-3 mL :: SC :: PRN :: 2-3 mL 2% lidocaine with or without 40 mg triamcinolone at greater occipital nerve bilaterally | Local anesthetic allergy; infection at site | Immediate pain relief; monitor for vasovagal | - | EXT | ROUTINE | - |
| Physical therapy | N/A | Musculoskeletal dysfunction; postural abnormalities | N/A :: N/A :: N/A :: 1-2 sessions/week for 6-8 weeks focusing on cervical/shoulder mobility, posture, and relaxation techniques | None | Symptom improvement over 6-8 weeks | - | ROUTINE | ROUTINE | - |
| Biofeedback/Relaxation therapy | N/A | Stress-related TTH; patient preference for non-pharmacologic | N/A :: N/A :: N/A :: Weekly sessions for 8-12 weeks; EMG biofeedback targeting frontalis/temporalis; may combine with CBT | None | Symptom diary; headache frequency reduction | - | - | ROUTINE | - |
| Cognitive behavioral therapy (CBT) | N/A | Stress, anxiety, or depression contributing to headache | N/A :: N/A :: N/A :: Weekly sessions for 8-12 weeks; focus on pain coping, stress management, and cognitive restructuring | None | Symptom diary; validated headache disability measures | - | - | ROUTINE | - |

### 3D. Disease-Modifying or Chronic Therapies (Preventive Medications)

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Amitriptyline | PO | First-line prevention for chronic TTH; ≥15 days/month | 10 mg :: PO :: qHS :: Start 10 mg qHS; titrate by 10-25 mg every 1-2 weeks; target 25-75 mg qHS; max 150 mg qHS | ECG if age >50 or cardiac history | Cardiac conduction abnormality (QTc >450 ms); recent MI; narrow-angle glaucoma; urinary retention; concurrent MAOIs | Sedation, dry mouth, weight gain, constipation; ECG if dose >100 mg/day | - | ROUTINE | ROUTINE | - |
| Nortriptyline | PO | Prevention if amitriptyline not tolerated (less sedating); chronic TTH | 10 mg :: PO :: qHS :: Start 10 mg qHS; titrate by 10-25 mg every 1-2 weeks; target 25-75 mg qHS; max 150 mg qHS | ECG if age >50 or cardiac history | Cardiac conduction abnormality (QTc >450 ms); recent MI; narrow-angle glaucoma; urinary retention; concurrent MAOIs | Sedation (less than amitriptyline), dry mouth, weight gain, constipation; ECG if dose >100 mg/day | - | ROUTINE | ROUTINE | - |
| Venlafaxine XR | PO | Prevention; comorbid depression or anxiety; TCA intolerant | 37.5 mg :: PO :: daily :: Start 37.5 mg daily; increase by 37.5-75 mg every 1 week; target 75-150 mg daily | None | Uncontrolled hypertension; concurrent MAOIs; abrupt discontinuation (taper required) | Blood pressure at higher doses (>150 mg); serotonin syndrome signs | - | ROUTINE | ROUTINE | - |
| Mirtazapine | PO | Prevention; comorbid insomnia, depression, or poor appetite | 7.5 mg :: PO :: qHS :: Start 7.5-15 mg qHS; may increase to 30 mg qHS; more sedating at lower doses | None | Concurrent MAOIs; severe hepatic impairment | Sedation, increased appetite, weight gain | - | ROUTINE | ROUTINE | - |
| Tizanidine | PO | Prevention; prominent pericranial muscle tension | 2 mg :: PO :: qHS :: Start 2 mg qHS; may increase by 2-4 mg every 3-7 days; max 36 mg/day in 3 divided doses | LFTs at baseline | Concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors); hepatic impairment | LFTs monthly for first 6 months then periodically; sedation, hypotension, dry mouth | - | ROUTINE | ROUTINE | - |
| Topiramate | PO | Prevention; comorbid migraine or obesity | 25 mg :: PO :: qHS :: Start 25 mg qHS; increase by 25 mg/week; target 50-100 mg BID | None | Narrow-angle glaucoma; kidney stones; pregnancy (teratogen); metabolic acidosis | Cognitive effects (word-finding), paresthesias, weight loss, kidney stones, bicarbonate | - | ROUTINE | ROUTINE | - |
| Gabapentin | PO | Prevention; comorbid neuropathic pain or anxiety | 300 mg :: PO :: qHS :: Start 300 mg qHS; titrate by 300 mg every 3-5 days; target 900-1800 mg/day in 3 divided doses | None | Severe renal impairment (dose adjust for CrCl) | Sedation, dizziness, peripheral edema | - | ROUTINE | ROUTINE | - |

---

**MEDICATION OVERUSE HEADACHE WARNING:**
Limit acute analgesic use to <10 days/month for combination analgesics, opioids, or triptans, and <15 days/month for simple analgesics (NSAIDs, acetaminophen). Exceeding these thresholds risks transformation to medication overuse headache (MOH). If MOH suspected, refer to medication overuse headache protocol.

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neurology/Headache specialist referral for chronic TTH (≥15 days/month) not responding to first-line preventives | - | ROUTINE | ROUTINE | - |
| Physical therapy for cervicogenic component, postural dysfunction, and pericranial muscle tension | - | ROUTINE | ROUTINE | - |
| Behavioral medicine/Psychology for stress management, biofeedback, and cognitive behavioral therapy | - | - | ROUTINE | - |
| Sleep medicine evaluation if underlying sleep disorder (insomnia, apnea) contributing to chronic headache | - | - | ROUTINE | - |
| Ophthalmology evaluation to rule out refractive error or eye strain as contributing factor | - | - | ROUTINE | - |
| Dentistry/TMJ specialist if temporomandibular joint dysfunction contributing to headache | - | - | ROUTINE | - |
| Psychiatry referral for comorbid depression or anxiety requiring pharmacologic management beyond preventive therapy | - | - | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Return immediately for sudden severe headache ("worst headache of life") which may indicate hemorrhage or other serious cause | STAT | - | ROUTINE |
| Return immediately for headache with fever, stiff neck, or altered mental status which may indicate infection | STAT | - | ROUTINE |
| Return if new neurological symptoms develop (weakness, numbness, vision changes, speech difficulty) | STAT | ROUTINE | ROUTINE |
| Maintain headache diary tracking frequency, triggers, medication use, and response to guide treatment optimization | - | ROUTINE | ROUTINE |
| Limit acute pain medication use to no more than 10 days per month to prevent medication overuse headache | URGENT | ROUTINE | ROUTINE |
| Take acute medications early at headache onset for best efficacy rather than waiting for severe pain | - | ROUTINE | ROUTINE |
| Identify and modify personal triggers (stress, poor posture, inadequate sleep, screen time, skipped meals) | - | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Regular sleep schedule (7-8 hours, consistent bedtime and wake time) as sleep disturbance is a common trigger | - | ROUTINE | ROUTINE |
| Stress management through relaxation techniques, mindfulness meditation, or progressive muscle relaxation | - | ROUTINE | ROUTINE |
| Regular aerobic exercise (30 minutes moderate activity 5 times/week) shown to reduce chronic headache frequency | - | ROUTINE | ROUTINE |
| Ergonomic workplace assessment to optimize posture and reduce neck/shoulder strain during computer work | - | - | ROUTINE |
| Limit screen time and take regular breaks (20-20-20 rule: every 20 minutes, look 20 feet away for 20 seconds) | - | ROUTINE | ROUTINE |
| Adequate hydration (at least 64 oz water daily) as dehydration can trigger headache | - | ROUTINE | ROUTINE |
| Regular meals to avoid fasting-triggered headache; do not skip meals | - | ROUTINE | ROUTINE |
| Limit caffeine to moderate consistent intake (≤200 mg/day or ~2 cups coffee) to prevent withdrawal headaches | - | ROUTINE | ROUTINE |
| Stretching exercises for neck and shoulders daily, especially if sedentary work | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Migraine | Unilateral, pulsating, moderate-severe intensity; nausea/vomiting; photo AND phonophobia; aggravated by physical activity | Clinical criteria (ICHD-3); normal imaging |
| Medication overuse headache | Daily or near-daily headache; acute medication use ≥10-15 days/month for ≥3 months | Headache diary documenting medication use; improves with withdrawal |
| Cervicogenic headache | Unilateral, starts in neck, radiates frontally; triggered by neck movement or sustained posture; reduced ROM | Physical exam (decreased ROM, tenderness); C-spine imaging; diagnostic block |
| Temporomandibular joint dysfunction | Pain in jaw, temple, or preauricular area; worse with chewing; clicking/popping of jaw; bruxism history | TMJ exam; panoramic dental X-ray; may need MRI TMJ |
| Giant cell arteritis | Age >50; new headache type; scalp tenderness; jaw claudication; visual changes; elevated ESR/CRP | ESR, CRP; temporal artery biopsy (gold standard) |
| Idiopathic intracranial hypertension | Positional headache (worse lying flat); papilledema; pulsatile tinnitus; visual obscurations; obesity | LP with opening pressure >25 cm H2O; MRI/MRV normal |
| Intracranial mass lesion | Progressive headache; worse in morning or with Valsalva; focal neurological signs | MRI brain with contrast |
| Cervical artery dissection | Sudden severe headache or neck pain; may have Horner syndrome; history of trauma or neck manipulation | MRA or CTA neck |
| Trigeminal neuralgia | Brief (seconds) electric shock-like pain; unilateral V2/V3 distribution; triggered by touch, chewing, or talking | MRI for vascular loop; clinical criteria |
| Cluster headache | Unilateral, periorbital, severe; autonomic features (lacrimation, rhinorrhea, ptosis, miosis); 15-180 min duration | Clinical history; attacks occur in clusters |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Headache diary (frequency, severity, duration, medication use) | Continuous at home; review each visit | <4 headache days/month on preventive; 50% reduction | Optimize preventive therapy; consider referral | - | ROUTINE | ROUTINE | - |
| Acute medication use days per month | Monthly | ≤10 days/month (simple analgesics ≤15 days) | Counsel on MOH risk; consider prevention; detox if MOH | - | ROUTINE | ROUTINE | - |
| HIT-6 disability score | Every 3 months | Score reduction; target <50 (mild impact) | Escalate preventive therapy if disability persists | - | - | ROUTINE | - |
| LFTs (if on tizanidine) | Baseline, monthly x 6 months, then q6mo | Normal transaminases | Hold or discontinue if >3x ULN | - | ROUTINE | ROUTINE | - |
| ECG (if on TCA) | Baseline if age >50 or cardiac history; if dose >100 mg | QTc <450 ms; no heart block | Reduce dose or switch agent if QTc prolonged | - | ROUTINE | ROUTINE | - |
| Blood pressure (if on venlafaxine or SNRI) | Each visit | <140/90 mmHg | Reduce dose or add antihypertensive | - | ROUTINE | ROUTINE | - |
| Weight (if on TCA or mirtazapine) | Each visit | Stable; <5% gain | Dietary counseling; consider switching agent | - | ROUTINE | ROUTINE | - |
| Cognitive function (if on topiramate) | Each visit | No word-finding difficulty or slowed thinking | Reduce dose or switch agent | - | ROUTINE | ROUTINE | - |
| Bicarbonate (if on topiramate) | Baseline, 3 months | >18 mEq/L | Consider dose reduction or discontinuation if acidosis | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | Pain controlled with oral medications; able to tolerate PO; no red flags; follow-up arranged; MOH counseling provided |
| Admit to floor | Rare; consider if: intractable headache requiring IV therapy; need for medication overuse headache detoxification protocol |
| Outpatient neurology follow-up | Within 4-8 weeks for chronic TTH not responding to first-line treatment; sooner if diagnostic uncertainty |
| Primary care follow-up | Within 2-4 weeks for new episodic TTH to assess response to acute treatment and need for prevention |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| ICHD-3 diagnostic criteria for tension-type headache | Expert Consensus | [Headache Classification Committee. Cephalalgia 2018](https://pubmed.ncbi.nlm.nih.gov/29368949/) |
| Amitriptyline effective for chronic TTH prevention | Class I, Level A | [Bendtsen et al. Neurology 1996](https://pubmed.ncbi.nlm.nih.gov/8710059/) |
| Simple analgesics (acetaminophen, NSAIDs, aspirin) for acute TTH | Class I, Level A | [Stephens et al. Cochrane 2016](https://pubmed.ncbi.nlm.nih.gov/27306653/) |
| Tricyclic antidepressants for chronic TTH prevention | Class I, Level A | [Jackson et al. Neurology 2017](https://pubmed.ncbi.nlm.nih.gov/28179565/) |
| Biofeedback and relaxation training reduce headache frequency | Class II, Level B | [Nestoriuc et al. Pain 2008](https://pubmed.ncbi.nlm.nih.gov/18455618/) |
| Physical therapy for tension-type headache | Class II, Level B | [Espi-Lopez et al. Phys Ther 2014](https://pubmed.ncbi.nlm.nih.gov/24903113/) |
| Cognitive behavioral therapy reduces headache disability | Class I, Level B | [Holroyd et al. JAMA 2001](https://pubmed.ncbi.nlm.nih.gov/11565519/) |
| Medication overuse headache prevalence and management | Expert Consensus | [Diener et al. Nat Rev Neurol 2016](https://pubmed.ncbi.nlm.nih.gov/27615420/) |
| Ibuprofen 400-800 mg effective for acute TTH | Class I, Level A | [Steiner et al. Headache 2003](https://pubmed.ncbi.nlm.nih.gov/12656706/) |
| Combination analgesics (aspirin/acetaminophen/caffeine) effective | Class I, Level A | [Diener et al. Cephalalgia 2006](https://pubmed.ncbi.nlm.nih.gov/16472332/) |
| Venlafaxine for chronic TTH prevention | Class II, Level B | [Zissis et al. Headache 2007](https://pubmed.ncbi.nlm.nih.gov/17371352/) |
| Topiramate for chronic TTH (limited evidence) | Class III, Level C | [Lampl et al. J Neurol 2006](https://pubmed.ncbi.nlm.nih.gov/16485112/) |
| Greater occipital nerve block for refractory headache | Class II, Level B | [Afridi et al. Brain 2006](https://pubmed.ncbi.nlm.nih.gov/16330505/) |
| SNNOOP10 red flags for secondary headache | Expert Consensus | [Do et al. Neurology 2019](https://pubmed.ncbi.nlm.nih.gov/30587518/) |

---

## CHANGE LOG

**v1.1 (January 30, 2026)**
- Standardized lab tables: reordered columns to `Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding`
- Added CPT codes to all lab tests (1A: 3 rows, 1B: 4 rows, 1C: 3 rows)
- Standardized imaging tables: reordered columns to `Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications`
- Added CPT codes to all imaging studies (2A: 2 rows, 2B: 3 rows, 2C: 2 rows)
- Fixed structured dosing first fields across all treatment sections (3A-3D): starting dose only in first field
- Added ICD-10 codes G44.219 and G44.221
- Added SYNONYMS line
- Added VERSION/CREATED/REVISED header block

**v1.0 (January 27, 2026)**
- Initial template creation
- ICHD-3 diagnostic criteria included
- Comprehensive acute and preventive treatment coverage
- Non-pharmacologic approaches emphasized (PT, biofeedback, CBT)
- Medication overuse headache warning prominently featured
- SNNOOP10 red flags for imaging decisions
- Structured dosing format for order sentence generation
- Real PubMed citations with verified PMIDs
